# ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Source: https://onco.cc/trials/nct02029443/  
OnCo record `nct02029443` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Acalabrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.

## Summary

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia is a phase 1/2 interventional study registered as NCT02029443 by Acerta Pharma BV, with 306 participants enrolled, started 2014-01-30 and due to reach its primary completion in 2021-07-15. Interventions recorded: Acalabrutinib. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02029443
- Phase: 1/2
- Setting: A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
- Sponsor: Acerta Pharma BV
- Enrolled: 306
- Outcomes: Number of Participants With Dose Limiting Toxicities (DLTs) in Phase 1: Cohort 1 0 participants vs Cohort 2a 0 participants vs Cohort 2b 0 participants vs Cohort 3 0 participants vs Cohort 4a 0 participants vs Cohort 4b 0 participants

## Sources

- ClinicalTrials.gov NCT02029443: https://clinicaltrials.gov/study/NCT02029443

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Richter transformation of chronic lymphocytic leukaemia](https://onco.cc/cancers/richter-transformation-cll/), [T-cell prolymphocytic leukaemia](https://onco.cc/cancers/t-cell-prolymphocytic-leukaemia/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- key papers: [Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia](https://onco.cc/key-papers/paper-acalabrutinib-cll-n-engl-j-med-2016/)

---
JSON: https://onco.cc/api/v1/entities/nct02029443.json